HRMY vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HRMY presents a dichotomy between a rock-solid balance sheet and deteriorating earnings performance. The Piotroski F-Score of 4/9 indicates stable financial health, supported by an exceptionally low Debt/Equity ratio (0.19) and strong liquidity (Current Ratio 3.60). However, these strengths are offset by a severe -55% YoY earnings contraction and a bearish insider sentiment characterized by C-suite selling. While the stock trades near its Graham Number ($30.21) and boasts an attractive Forward P/E of 4.99, the disconnect between analyst targets ($42.00) and current growth trends suggests significant volatility ahead.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HRMY vs MRK: Head-to-Head Comparison
This page compares Harmony Biosciences Holdings, Inc. (HRMY) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.